Pay in 4 interest-free payments of $5.21 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Inhibition of Monocyte Adhesion to Endothelial Cells and Attenuation of Atherosclerotic Lesion by a Glucagon-like Peptide-1 Receptor Agonist, Exendin-4
Cost, Insurance Driving Move to Compounded Drugs Compounded GLP-1 medications are not approved by the FDA, and the agency issued a warning in June calling them potentially risky for patients. This hasnt stopped patients from switching to the unapproved drugs, and 35% of patients who took compounded GLP-1s left from a name brand drug, according to Gallup
Primary Research Extensive primary research was conducted after acquiring basic knowledge about the global GLP-1 agonists market scenario through secondary research
Pharma companies must, therefore, carefully consider the legal and regulatory status of these formulations
Your Initial Consultation Your journey begins with an initial consultation
Preclinical studies showed that GLP-1RAs reduce cytokine production, attenuate pulmonary inflammation and preserve lung function in rats and mice with experimental lung injury (38, 39)
